Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1196158 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:The present study investigated whether maternal periodontal disease modifies the microRNA expression profile in adult offspring. *************************************************************** This study was supported by the São Paulo Research Foundation (FAPESP) [grant #2019/04183-9; #2022/08872-6; #2023/03786-7; #2023/12488-0; #2023/01400-4] and CNPq [grant 151151/2023-7], São Paulo, SP, Brazil. The grants #2019/04183-9; #2023/12488-0; #2023/01400-4 and 151151/2023-7 were awarded to the author Maria Sara de Lima Coutinho Mattera. The grant #2022/08872-6 was awarded to Heloisa Macedo Sampaio. The grant #2023/03786-7 was awarded to Gabriele Fernandes Baliero. ***************************************************************
2024-12-28 | GSE281235 | GEO
Project description:similar methods as in Gomez-Picos et al. (2022) and Nguyen et al. (2023)
2023-12-18 | GSE249932 | GEO
Project description:RNAseq of CD4 cells from 83 individuals with musculoskeletal complains (age 51y, range 19-86. male 22%) were collected at the Rheumatology Clinic during 2022-2023 . Cells were activated with anti-CD3 for 48 hours.
2025-01-02 | GSE282517 | GEO
Project description:Metagenomes from Winam Gulf, Lake Victoria (2022-2023), Lake Simbi (2022-2023), and Lake Naivasha (2022)
| PRJNA1119566 | ENA
Project description:EFSA Confirm 2023 (2022 data)
| PRJEB84456 | ENA
Project description:Diphtheria The Netherlands 2022-2023
| PRJEB80212 | ENA
Project description:Acinetobacter baumannii outbreak 2022-2023
| PRJEB62407 | ENA
Project description:New onsets of chronic urticaria (CU) have been reported after repeated immunizations, mainly with the Moderna mRNA-1273 vaccine (Spikevax). This study aims to evaluate patients with CU after COVID-19 mRNA vaccination. The contribution of SARS-Cov2 infection, atopy and IgE against the vaccine was analyzed. We monitored the features of patients who developed CU after vaccination in the Canton of Vaud through two surveys conducted in 2022 and 2023. Fifty individuals with CU underwent blood tests, and their results were compared with individuals without a history of urticaria (N=135). The presence of anti-vaccine IgE was detected with basophil activation tests (BAT). We assessed anti-SARS-Cov2 humoral response, and the presence of IgEs against common respiratory allergens (Phadiatop) as a surrogate for atopy. Post-vaccination CU occurred after a median interval of 10 days and significantly more after the Spikevax booster, affecting middle-aged individuals (median 41, 66% females). In 2023, CU was still active in 53% of the cases. Inducible forms of CU, primarily dermographism, were reported in 54% (2022) and 61% (2023) of the cases. BAT positivity was not specific to CU, anti-nucleocapsid positivity, or atopy but was significantly associated with higher anti-spike neutralizing activities and younger age. Four CU patients tolerated an additional dose of mRNA vaccine with no disease exacerbation/recurrence. The spikevax booster induced anti-vaccine IgE independently of CU, the latter being not directly associated with COVID-19 infection nor atopy. The tolerance to a new booster in 4/4 patients suggests that the Spikevax vaccine indirectly triggered CU in predisposed individuals.
2024-07-26 | GSE272645 | GEO